PL3130592T3 - Analogi związków 4h-pirazolo[1,5-α]benzimidazolowych jako inhibitory PARP - Google Patents
Analogi związków 4h-pirazolo[1,5-α]benzimidazolowych jako inhibitory PARPInfo
- Publication number
- PL3130592T3 PL3130592T3 PL15777444T PL15777444T PL3130592T3 PL 3130592 T3 PL3130592 T3 PL 3130592T3 PL 15777444 T PL15777444 T PL 15777444T PL 15777444 T PL15777444 T PL 15777444T PL 3130592 T3 PL3130592 T3 PL 3130592T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazolo
- analogues
- parp inhibitors
- benzimidazole compound
- benzimidazole
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- -1 of 4h-pyrazolo[1,5- ]benzimidazole compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144173.0A CN104974161B (zh) | 2014-04-10 | 2014-04-10 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CN201510113090 | 2015-03-13 | ||
| EP15777444.9A EP3130592B1 (en) | 2014-04-10 | 2015-03-30 | Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors |
| PCT/CN2015/075363 WO2015154630A1 (zh) | 2014-04-10 | 2015-03-30 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3130592T3 true PL3130592T3 (pl) | 2020-05-18 |
Family
ID=54287319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15777444T PL3130592T3 (pl) | 2014-04-10 | 2015-03-30 | Analogi związków 4h-pirazolo[1,5-α]benzimidazolowych jako inhibitory PARP |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9856262B2 (en:Method) |
| EP (1) | EP3130592B1 (en:Method) |
| JP (1) | JP6359175B2 (en:Method) |
| KR (1) | KR101921486B1 (en:Method) |
| CN (1) | CN106459057B (en:Method) |
| AU (1) | AU2015245786B2 (en:Method) |
| BR (1) | BR112016023397B1 (en:Method) |
| CA (1) | CA2944801C (en:Method) |
| DK (1) | DK3130592T3 (en:Method) |
| ES (1) | ES2754590T3 (en:Method) |
| HU (1) | HUE047410T2 (en:Method) |
| IL (1) | IL248258B (en:Method) |
| MX (1) | MX368496B (en:Method) |
| NZ (1) | NZ725165A (en:Method) |
| PL (1) | PL3130592T3 (en:Method) |
| PT (1) | PT3130592T (en:Method) |
| RU (1) | RU2672722C2 (en:Method) |
| SA (1) | SA516380051B1 (en:Method) |
| SG (1) | SG11201608438YA (en:Method) |
| TW (1) | TWI671301B (en:Method) |
| WO (1) | WO2015154630A1 (en:Method) |
| ZA (1) | ZA201607736B (en:Method) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974161B (zh) * | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| WO2017054755A1 (zh) * | 2015-09-30 | 2017-04-06 | 湖北生物医药产业技术研究院有限公司 | 4H-吡唑并[1, 5-α]苯并咪唑类化合物的盐型、晶型及其制备方法和中间体 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN110536892B (zh) | 2017-04-27 | 2023-05-12 | 拜耳动物保健有限责任公司 | 新的二环吡唑衍生物 |
| CN115028641B (zh) * | 2022-07-19 | 2024-05-28 | 湖南大学 | 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025056690A1 (en) | 2023-09-12 | 2025-03-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4 |
| CN116969954B (zh) * | 2023-09-21 | 2023-11-28 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含内酰胺的三环稠合杂环化合物及其应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117534677B (zh) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含亚胺的三环稠合杂环化合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916051A (en) * | 1987-04-07 | 1990-04-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| JP4926720B2 (ja) * | 2003-12-22 | 2012-05-09 | スミスクライン ビーチャム （コーク） リミテッド | Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法 |
| WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
| WO2007144669A1 (en) * | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| ES2559679T3 (es) * | 2006-06-20 | 2016-02-15 | Abbvie Inc. | Pirazoloquinazolinonas como inhibidores de PARP |
| GB0701273D0 (en) | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| PL2656843T3 (pl) | 2012-04-26 | 2015-08-31 | Synbias Pharma Ag | Estry bendamustyny i związki pokrewne i ich medyczne zastosowanie |
| EA027628B1 (ru) | 2012-05-04 | 2017-08-31 | Мерк Патент Гмбх | Производные пирролотриазинона |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| JP2015522557A (ja) | 2012-06-07 | 2015-08-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | タンキラーゼのピロロピリミドン及びピロロピリドン阻害剤 |
| AU2013288265B2 (en) | 2012-07-09 | 2017-04-06 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| CN104507912B (zh) * | 2012-08-08 | 2016-09-28 | 默克专利股份公司 | (氮杂-)异喹啉酮衍生物 |
| CN104974161B (zh) | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
-
2015
- 2015-03-30 BR BR112016023397-2A patent/BR112016023397B1/pt active IP Right Grant
- 2015-03-30 NZ NZ725165A patent/NZ725165A/en unknown
- 2015-03-30 AU AU2015245786A patent/AU2015245786B2/en active Active
- 2015-03-30 CA CA2944801A patent/CA2944801C/en active Active
- 2015-03-30 HU HUE15777444A patent/HUE047410T2/hu unknown
- 2015-03-30 US US15/302,588 patent/US9856262B2/en active Active
- 2015-03-30 JP JP2017504223A patent/JP6359175B2/ja active Active
- 2015-03-30 KR KR1020167031520A patent/KR101921486B1/ko active Active
- 2015-03-30 RU RU2016144202A patent/RU2672722C2/ru active
- 2015-03-30 DK DK15777444T patent/DK3130592T3/da active
- 2015-03-30 CN CN201580017657.1A patent/CN106459057B/zh active Active
- 2015-03-30 PT PT157774449T patent/PT3130592T/pt unknown
- 2015-03-30 WO PCT/CN2015/075363 patent/WO2015154630A1/zh not_active Ceased
- 2015-03-30 ES ES15777444T patent/ES2754590T3/es active Active
- 2015-03-30 PL PL15777444T patent/PL3130592T3/pl unknown
- 2015-03-30 MX MX2016013265A patent/MX368496B/es active IP Right Grant
- 2015-03-30 EP EP15777444.9A patent/EP3130592B1/en active Active
- 2015-03-30 SG SG11201608438YA patent/SG11201608438YA/en unknown
- 2015-04-08 TW TW104111236A patent/TWI671301B/zh active
-
2016
- 2016-10-09 IL IL248258A patent/IL248258B/en active IP Right Grant
- 2016-10-10 SA SA516380051A patent/SA516380051B1/ar unknown
- 2016-11-09 ZA ZA2016/07736A patent/ZA201607736B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287517A (en) | Benzimidazole compounds as c-kit inhibitors | |
| PL3130592T3 (pl) | Analogi związków 4h-pirazolo[1,5-α]benzimidazolowych jako inhibitory PARP | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| IL252575A0 (en) | History of 2,4-dioxo-quinazoline-6-sulfonamide as parg inhibitors | |
| ZA201801032B (en) | Bicyclic compounds as atx inhibitors | |
| IL254318A0 (en) | History of benzaimidazoles as bromodomain inhibitors | |
| IL255570A (en) | Bicyclic compounds as atx inhibitors | |
| PT3109223T (pt) | Mistura para o tratamento de fertilizantes contendo ureia | |
| IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
| ZA201808345B (en) | Capsules comprising benzylpropargylethers for use as nitrification inhibitors | |
| IL266745B (en) | Benzodiazolonium compounds as enac inhibitors | |
| IL254476A0 (en) | Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists | |
| IL256226A (en) | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors | |
| ZA201704462B (en) | New benzimidazole derivatives as antihistamine agents | |
| ZA201700518B (en) | Use of active compound compositions | |
| ZA201607256B (en) | Active compound combinations | |
| GB201508787D0 (en) | Pharmaceutically active compounds | |
| GB201520189D0 (en) | Compound for use | |
| GB201403538D0 (en) | Pharmacologically active compounds | |
| TWM489712U (en) | Structure of nailing machine |